end-stage renal disease


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to end-stage renal disease: kidney disease

end-stage renal disease

 
chronic renal failure that is irreversible; at this stage serum creatinine and blood urea nitrogen (BUN) levels continue to rise and there is uremia with impairment of all body systems.

re·nal fail·ure

loss of renal function, either acute or chronic, that results in azotemia and syndrome of uremia.

end-stage renal disease

End-organ disease, end-stage renal failure The decompensated stage of chronic renal failure, defined as renal insufficiency of a degree that requires dialysis or kidney transplantation for survival  Epidemiology 30% of ESRD is linked to DM and HTN, the most common causes of ESRD; ESRD is seen in kidneys subjected to chronic dialysis Costs ESRD programs for 200,000 Pts–0.08% of US population, cost $6 x 109–0.8% of US health care budget Complications Infection, possibly due to impaired macrophage Fc-receptor function  Management Kidney transplantation, see there Prognosis 1-yr survival of graft, ±94%; half-life from living donor grafts, ±22 yrs, from cadaveric grafts, ±14 yrs.

End-stage renal disease (ESRD)

Total kidney failure; chronic kidney failure is diagnosed as ESRD when kidney function falls to 5-10% of capacity.
References in periodicals archive ?
Commenting on the IDE approval, William Fox, Executive Chairman of Nephros, said, "According to industry sources, the number of End-Stage Renal Disease patients worldwide is expected to grow approximately 50% to 2.
The trial is a prospective, multi-center trial whereby stable End-Stage Renal Disease patients will be monitored during a first hemodialysis (control) period using their current hemodialysis machine with a conventional high-flux dialyzer, followed by a second hemodiafiltration (test) period using their current hemodialysis machine, the Nephros H2H Module, and the Nephros MD 220 Hemodiafilter.
headquartered in New York, is a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider.
More than 300,000 people in the United States, or just over one in 1,000 Americans, are being treated for end-stage renal disease (ESRD), which occurs when the kidneys are destroyed by disease.
In addition, studies show that delayed referral of patients with end-stage renal disease to nephrologists, a kidney disease specialist, results in longer hospital stays and higher costs, compared to patients who have been regularly monitored by a nephrologist.
Whereas the vast majority of end-stage renal disease patients qualify for either hemodialysis or peritoneal dialysis, studies indicate many patients do not feel they are well educated on all of their treatment options.
Vascular access failure is a major complication in providing care to patients on hemodialysis to treat end-stage renal disease (ESRD).
American Access Care is a management company operating freestanding outpatient vascular access centers dedicated to patients suffering from end-stage renal disease (ESRD).
The risk of such damage in end-stage renal disease patients can be lowered by regularly taking phosphate binders.
The two clinical studies approved under the IND are evaluating the safety and feasibility of Vascugel[TM] for the maintenance of vascular patency after creation of arteriovenous (AV) access graft and AV fistula, respectively, for patients undergoing dialysis for the treatment of end-stage renal disease (ESRD).